On October 21, 2021 Artiva Biotherapeutics, Inc., ("Artiva") an oncology company focused on developing and commercializing off-the-shelf, allogeneic natural killer (NK) cell-based therapies to treat cancer, reported an upcoming presentation describing AB-201, an anti-HER2 CAR-NK cell therapy candidate, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 36th Annual Meeting and Pre-Conference Programs to be held November 10-14, 2021, virtually and in-person at the Walter E. Washington Convention Center in Washington, D.C (Press release, Artiva Biotherapeutics, OCT 21, 2021, View Source [SID1234591680]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The full abstract is scheduled to be available on the SITC (Free SITC Whitepaper) website on November 9, 2021.
Poster Presentation Info:
Title: Development of AB-201, a novel allogeneic anti-HER2-specific CAR-NK cell therapy for the treatment of HER2+ tumors
Abstract Number: #129
Date: November 12 – 13, 2021
Time: 7:00 am – 8:30 pm ET
Location: Hall E
About HER2+ Solid Tumors
HER2 is a receptor tyrosine kinase that is overexpressed on many solid tumors, including breast, gastric, and bladder cancers. It is estimated that there are over 50,000 patients diagnosed annually in U.S. with tumors having high HER2 expression, with overexpression found in approximately 20% of breast cancer cases and in over 10% of bladder and gastric cancers. Currently, there are eight approved HER2-directed therapies including monoclonal antibodies, antibody-drug conjugates, and small molecule kinase inhibitors. While many patients with advanced HER2+ cancers derive meaningful benefit from HER2-targeted therapies, they typically progress beyond approved therapies, and treatment of these patients remains a large unmet medical need.
About AB-201
AB-201 is an allogeneic anti-HER2 CAR-NK cell therapy candidate manufactured from cord blood, containing a proprietary HER2 antigen recognition domain. Artiva is developing AB-201 for the treatment of HER2-overexpressing tumors, such as breast, gastric, and bladder cancers. The company is currently manufacturing AB-201 in large scale bioreactors, resulting in potentially thousands of doses of product from a single donor cord blood unit.